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Abstract
Background: Computerized Clinical Records, which are incorporated in primary health care practice, have great
potential for research. In order to use this information, data quality and reliability must be assessed to prevent
compromising the validity of the results.
The aim of this study is to validate the diagnosis of hypertension and diabetes mellitus in the computerized clinical
records of primary health care, taking the diagnosis criteria established in the most prominently used clinical
guidelines as the gold standard against which what measure the sensitivity, specificity, and determine the
predictive values.
The gold standard for diabetes mellitus was the diagnostic criteria established in 2003 American Diabetes
Association Consensus Statement for diabetic subjects. The gold standard for hypertension was the diagnostic
criteria established in the Joint National Committee published in 2003.
Methods: A cross-sectional multicentre validation study of diabetes mellitus and hypertension diagnoses in
computerized clinical records of primary health care was carried out. Diagnostic criteria from the most prominently
clinical practice guidelines were considered for standard reference.
Sensitivity, specificity, positive and negative predictive values, and global agreement (with kappa index), were
calculated. Results were shown overall and stratified by sex and age groups.
Results: The agreement for diabetes mellitus with the reference standard as determined by the guideline was
almost perfect ( = 0.990), with a sensitivity of 99.53%, a specificity of 99.49%, a positive predictive value of 91.23%
and a negative predictive value of 99.98%.
Hypertension diagnosis showed substantial agreement with the reference standard as determined by the guideline
( = 0.778), the sensitivity was 85.22%, the specificity 96.95%, the positive predictive value 85.24%, and the negative
predictive value was 96.95%. Sensitivity results were worse in patients who also had diabetes and in those aged 70
years or over.
Conclusions: Our results substantiate the validity of using diagnoses of diabetes and hypertension found within
the computerized clinical records for epidemiologic studies.
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In recent decades, Computerized Clinical Records (CCR)
are being used in the routine medical practice of pri-
mary health care (PHC) in the Spanish National Health
System (NHS). Indeed, by 2007, 98.8% of general prac-
tices were computerized and 88% of the population had
a primary care electronic health records [1]. There are
many software systems to manage the CCR. In Spain
the most frequently implemented CCR is the OMI-AP
®
program.
Other countries like Canada, the United States of
America, and some European Countries have a signifi-
cant experience using computerized health databases
obtained with PHC records [2-4]. The most widely used
is the GPRD (General Practice Research Database),
which contains information introduced prospectively
since 1987 by more than 1,500 general practitioners
(GPs) in the PHC of the United Kingdom and includes
7% of the population [5]. The GPRD has been widely
used for research studies, with over 700 associated
papers published up to date in peer-reviewed journals
[5].
Electronic Health Records provide great potential for
research, because of their ability to provide data for
large populations. Even though the CCR can be used for
research, it is important to note that the data are col-
lected primarily for routine clinical rather than for
researching purposes. Data quality and reliability must
be assessed by researchers who use the resources found
in the CCR in order to prevent compromising the
results.
There are several approaches found in the literature
but there is not an agreed upon standard approach to
evaluate the quality and accuracy.
Related validation studies have attempted to show
whether the cases with diagnostic codes indeed have
that condition. Two recent systematic reviews of valida-
tion studies within the GPRD have shown that most
(90%) of the coded diagnoses, from many diseases, are
‘validated’[6,7]. In order to perform these validations,
83% of them used sources of information external to the
GPRD, mostly questionnaires from GPs, hospital
reports, copies of the Medical history or comparisons
with disease rates obtained from other registries.
The validation of the diagnosis information included
in BIFAP (Base de Datos para la Investigación Farma-
coepidemiológica en Atención Primaria), population-
based database in Spain containing information of more
than 2.5 million patients, was carried out by sending
questionnaires to collaborating doctors requiring hospi-
tal reports and other information in paper format of the
clinical history and doctor’s activities reports [8]. Exter-
nal validations were also carried out comparing the
results with other sources of information, such as the
national health survey and the death registry.
In order to guarantee the quality of the studies per-
formed with the data from the CCR and because few
studies have evaluated the quality of those registries, it
is necessary to check their validity in our setting. The
abovementioned methodology, that used the medical
records of the second health care level as the standard
reference, does not seem appropriate for chronic dis-
eases such as hypertension (HTN) and diabetes mellitus
(DM), which mainly were diagnosed and followed up in
the PHC.
T h ea i mo ft h i ss t u d yi st ov a l i d a t et h ed i a g n o s i so f
HTN and DM coded in the CCR of PHC, taking the
diagnosis criteria established in the most prominently
used clinical guidelines as the gold standard.
Methods
Design
Cross-sectional validation study of the diagnoses of DM
and HTN in the CCR of PHC.
Setting
The study was carried out in the 21 health centers of
t h eh e a l t ha r e a4 ,i nt h en o r t h e a s tu r b a nz o n eo ft h e
Community of Madrid, which serves a population of
777,426 people. All health centers have computerized
patient records since at least for 10 years.
Sources of information
The CCR administered by the software OMI-AP
® were
structured around a list of episodes (problems in the
bio-psycho-social sphere, reasons for consultation, etc).
T h ee p i s o d e sa r el i s t e dw i t ha na l p h a n u m e r i cc o d e ,
which corresponds to the International Classification of
Primary Care (ICPC), and a description or clinical label.
The same code can be described by using many differ-
ent clinical labels.
It is possible to link these episodes with diagnostic
tests, prescriptions, protocols, therapeutic interventions,
referrals, temporary incapacity to work reports, and
free-text annotations. The laboratory results are automa-
tically recorded in the CCR.
In PHC, text and codes are entered by the GPs during
clinical care, as part of their routine clinical practice.
The CCR incorporates a user-friendly instrument to
encode episodes in order to make it acceptable and use-
ful to the GPs, who are not professional coders. This
instrument is a search system based on clinical labels
that assigns the code automatically. The program allows
the modification of the descriptions, but not the code
which could be substituted or erased if deemed
necessary.
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from the CCR of patients.
Inclusion and exclusion criteria
The study population comprised those patients who met
the following inclusion criteria: had at least one record
within the CCR in the health centers of health area 4 as
of January 1
st 2010; over 18 years of age; had an ICPC
code in their CCR corresponding to DM (32,377
patients with code T90) or to HTN (91,065 patients
with codes K86 or K87), respectively.
Patients were not included if they met any of the fol-
lowing exclusion criteria: had not at least one plasma
glucose measurement (7.3%) or two Blood pressure (BP)
measurements (22.9%) in their CCR for the validation of
DM and HTN, respectively.
Samples
Given the absence of reference information over the
proportion of incorrectly classified cases (false negatives
or false positives), the maximum indetermination was
assumed (p = (1-p) = 0.5).
With this assumption, and in order to obtain a confi-
dence of 95% and a precision of 5%, the required sample
size was 384 patients for each variable. We increased it
up to 423 to adjust for a foreseeable loss of 10%
between the sampling and validation of the diagnosis
(change of address, death or other reasons).
Four different samples of patients were obtained: with
DM code (sample 1), without DM code (sample 2), with
HTN code (sample 3), and without HTN code (sample
4) in the CCR. The first two were used to validate the
episodes of DM and the latter two were used to validate
the episodes of HTN.
Samples 1 and 3 were obtained by simple random way
whilst samples samples 2 and 4 were obtained by indivi-
dual matching by age and sex with samples 1 and 3,
respectively.
Methods
Diagnostic test aims to correctly classify patients and
healthy for a disease or clinical condition. The validation
of a diagnostic test is performed by comparing their
results, both positives and negatives, with those obtained
by the best instrument for measuring the phenomenon
under study (gold standard).
In this study, documented diagnosis of DM and HTN
were considered as the diagnostic tests. In order to per-
form the validation, they were compared against the
gold standards.
The gold standard for DM were the diagnostic criteria
established in 2003 American Diabetes Association Con-
sensus Statement for diabetic subjects, that that were
still in effect in 2010 [9]. The reference diagnostic cri-
teria for DM were shown in Table 1.
T h eg o l ds t a n d a r df o rH T Nw ere the diagnostic cri-
teria established in the Joint National Committee (JNC
7) of the United States published in 2003, which were
shown in Table 2[10].
These criteria agree with recommendations given by
other major scientific societies, such as the World
Health Organization [11], the European Society for the
Study of Diabetes (EASD) [12], the European Society of
Hypertension (ESH) [13,14], the European Society of
Cardiology [14], the Canadian Diabetes Association [15]
and with the recommended guidelines in Spain [16-19].
Subjects of samples 1 and 2 were considered with DM
as long as they fulfilled at least one of the criteria
described in Table 1. Subjects from samples 3 and 4
that fulfilled any criteria from Table 2 were considered
patients with HTN.
We consulted the computerized medical records of
patients to verify concordance with the above criteria.
The validation algorithm is shown in the Figure 1.
The evaluation team consisted of three general practi-
tioners, with experience using the OMI-AP program.
We conducted a peer evaluation with two reviewers and
a third evaluator who resolved discrepancies.
Statistical Analysis
A descriptive analysis of the study population and sam-
ples was carried out. The age was expressed by means
of average percentiles 25 and 75, and the qualitative
variables were summarized with their relative frequency.
Table 1 Diabetes Mellitus diagnostic criteria.
Diabetes mellitus diagnostic criteria
￿ Fasting plasma glucose ≥ 126 mg/dl (7.0 mmol/l).
￿ Symptoms of hyperglycemia (polyuria, polydipsia, and unexplained
weight loss) and a casual (random) plasma glucose ≥ 200 mg/dl (11.1
mmol/l).
￿ 2-h plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during the 75 g oral
glucose tolerance test.
￿ On therapy for Diabetes mellitus and previous diagnosis of Diabetes
Mellitus in medical records.
￿ Gestational diabetes mellitus:
- To make a diagnosis of Gestational diabetes mellitus, at least two
of the following plasma glucose values must be found in the 100
g oral glucose tolerance test:
■ Fasting plasma glucose: ≥ 95 mg/dl
■ 1h :≥ 180 mg/dl
■ 2h :≥ 155 mg/dl
■ 3h :≥ 140 mg/dl.
- On therapy for Diabetes mellitus and diagnosis of Gestational
diabetes mellitus in medical records.
* In the absence of unequivocal hyperglycemia, these criteria should be
confirmed by repeat testing on a different day.
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values (PPV) and negative predictive values (NPV) were
calculated, with their confidence intervals at 95% (CI),
overall and stratified by gender, age group and DM.
In addition, a sensitivity analysis was performed deter-
mining the relative impact on predictive values of varying
assumptions regarding the prevalence of DM and HTN.
The Sn is the proportion of cases with DM or HTN
codes in the CCR among those that fulfilled the
diagnosis criteria of Tables 1, respectively. The Sp is the
proportion of cases without DM or HTN code in the
CCR among those that did not fulfill the diagnosis cri-
teria. Positive predictive value is the probability that
people with DM or HTN code in the CCR meet the
diagnostic criteria, while negative predictive value is the
probability that people without DM or HTN code do
not meet the criteria.
We checked whether the Sn and Sp were different by
gender, age group and DM Through the homogeneity
test based on a c
2 statistic. In case that the application
conditions of the test were not met (any expected cell
count under 5), then the Fisher’s exact bilateral test was
used.
When diagnostic tests are applied to the population,
the proportion of those testing positive (apparent preva-
lence) can not be used as an estimation of the preva-
lence of a disease in that population, because the Sn
and Sp of these tests are usually less than 100%. Thus,
Table 2 Hypertension diagnostic criteria.
Hypertension diagnostic criteria
￿ Average of two or more properly measured, systolic blood pressure
readings on each of two or more office visits ≥ 140 mmHg (≥ 130
mmHg for patients with diabetes and chronic kidney disease)
￿ Average of two or more properly measured, diastolic blood pressure
readings on each of two or more office visits ≥ 90 mmHg (≥ 80 mmHg
for patients with diabetes and chronic kidney disease)
￿ On therapy with antihypertensive medications and diagnosis of
Hypertension in medical records.
Figure 1 Validation algorithm. DM: diabetes mellitus; HTN: hypertension.
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includes false positive cases and excludes cases that are
false negatives, so in order to estimate the true preva-
lence of a disease from diagnostic tests; it is required to
adjust for the misclassification resulting from the Sn
and Sp of the used test. In this study we have used the
formula proposed by Rogan and Gladen for this adjust-
ment [20].
True prevalence = (apparent prevalence + Sp − 1) / (Sn + Sp − 1)
The degree of overall agreement between the regis-
tered diagnosis and the reference standard, as well as
the inter-observer agreement, was determined by the
kappa index with their CI. According to this value, the
agreement was considered slight (≤ 0.20), fair (0.21-
0.40), moderate, (0.41-0.60), substantial (0.61-0.80) or
almost perfect agreement (≥ 0.81) [21].
The statistic analysis of the information was per-
formed with SPSS software (version 15.0, SPSS Inc.,
Chicago, Illinois), the CI of the kappa index and the pre-
dictive values were calculated with macros for SPSS of
the Applied Statistics Laboratory in Universidad Autón-
oma de Barcelona: !KAPPA and !DT, respectively
[22,23].
Ethical Aspects
In order to ensure the confidentiality, the study was
developed as stipulated in the Spanish Personal Data
Protection Law. The protocol of the study was approved
by the ethics committee of the Hospital Carlos III in
Madrid and all of the evaluators signed a confidentiality
clause.
Results
The main demographic characteristics of the population
of patients over 18 years old attended in the health area
4 with episodes of DM (ICPC T90) and HTN (ICPC
K 8 6o rK 8 7 )r e g i s t e r e di nt h eC C R ,a sw e l la st h e
selected samples are described in Table 3.
T h e7 . 3 %o fp a t i e n t sf r o ms a m p l e2( w i t h o u tD M
code) had to be excluded because there was not at least
one fasting plasma glucose. They were 64.5% males with
a mean age of 73.6 (SD 14.4) years. There were signifi-
cant differences in mean age between patients excluded
and not excluded.
The 22.9% of patients from sample 4 (without HTN
code) had to be excluded because there were not at
least two BP measurements. They were 36.1% males
with a mean age of 69.1 (SD 11.6) years. There were no
significant differences in mean age and female
Table 3 Main demographic characteristics of the population of patients over 18 years old attended in Health Area 4
and of samples.
N
(%)
Age (years)
median (IQR)
Age ≥ 70
years
(%)
Gender
female
(%)
DM
(%)
Patients with diagnosis code of diabetes (T-90) 32,377 (5.02) 71.15 (60.03-78.95) 52.37 50.83
Sample of patients with diagnosis code of diabetes (sample 1) 423 (1.31) 70.31 (60.22-78.20) 50.83 50.83
- Correct diagnosis (TP) 421 (99.53) 70.31 (60.25-78.43) 50.83 50.83
- Incorrect diagnosis (FP) 2 (0.47) 64.33 (51.22-77.44) 50 50
Patients without diagnosis code of diabetes (T-90) 612,896
(94.98)
43.63 (33.27-60.08) 14.85 56.34
Sample of patients without diagnosis code of diabetes (sample
2)
392 (0.06) 69.66 (59.57-78.05) 49.2 51.8
- Correct diagnosis (TN) 390 (99.49) 69.66 (59.52-78.03) 49.2 51.8
- Incorrect diagnosis (FN) 2 (0.51) 74.23 (62.79-85.67) 50 50
Patients with diagnosis code of hypertension (K-86 ó K-87) 91,065 (14.11) 71.96 (61.66-79.41) 54.53 58.58 21.55
Sample of patients with diagnosis code of hypertension (sample
3)
423 (0.46) 72.63 (61.56-79.40) 57.92 58.63 24.59
- Correct diagnosis (TP) 415 (98.11) 72.67 (61.65-79.40) 58.31 58.55 24.82
- Incorrect diagnosis (FP) 8 (1.89) 64.00 (55.18-
76.86)
37.5 62.5 12.5
Patients without diagnosis code of hypertension (K-86 or K-87) 554,208
(85.89)
41.47 (32.21-54.68) 10.52 55.65 2.3
Sample of patients diagnosis code of hypertension (sample 4) 326 (0.06) 70.35 (61.77-79.27) 57.98 57.06 14.72
- Correct diagnosis (TN) 254 (77.91) 71.68 (61.15-78.26) 53.15 57.48 8.66
- Incorrect diagnosis (FN) 72 (22.09) 77.74 (69.32-83.99) 75 55.56 36.11
IQ: interquartile range; TP: true positive; FP: false positive; TN: true negative; FN: false negative; DM: diabetes mellitus.
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from the sample.
The prevalence of patients diagnosed with DM was
5.02%, slightly higher in males and in patients aged 65
years or older. The prevalence of patients with diagnosis
of HTN was 14.11%, higher in women, in people aged
70 years or older and in patients with diagnosis of DM.
In our study, the diagnosis of DM was confirmed in
99.5% of the cases (sensitivity) and in 99.49% of those
without diagnosis of DM did not meet the diagnosis cri-
teria (specificity). There were no significant differences
when stratifying by age groups or sex.
The sensitivity of the diagnosis of HTN was 85.22%,
decreasing significantly in people over 69 years old
(81.76%) and in patients with diagnosis of DM (79.85).
The specificity of the diagnosis of HTN was 96.95%,
with no significant differences when stratifying by sex or
age groups (Table 4).
The degree of overall agreement between the diagno-
sis in the CCR and the standard of reference, measured
as the kappa index, was almost perfect for DM ( =
0.990), and substantial agreement for the HTN ( =
0.778), as shown in Table 4. The worst result was
obtained for HTN in the subgroup of patients with diag-
nosis of diabetes.
The degree of global inter-observers agreement, mea-
sured with the kappa index was very high, both for DM
( =0 . 9 8 8 )a n dH T N(  = 0.941), and for the different
categories of sex, age groups and diagnosed diabetes. In
all cases, the kappa index was higher than 0.880.
Table 5 shows the apparent prevalences (diagnosed in
the CCR), true prevalences (fulfillment of the diagnosis
criteria) as well as the positive and negative predictive
values. The true prevalences were, for both diseases,
higher than the apparent prevalences. The between
them was 0.89% for the DM diagnosis and 21.45% for
HTN, which increased up to 32.36% in patients diag-
nosed with diabetes. The probability that the diagnostic
criteria could be confirmed in patients with diagnosed
DM was 91.23% and 99.98% in HTN.
Given that the PPV is directly proportional to the pre-
valence of the disease and the NPV is inversely propor-
tional to the prevalence, we estimated the PPV and
NPV for different true prevalences of HTN and DM
(Table 6).
Discussion
The results of the study show a very high agreement of
the diagnosis of DM in the CCR with the gold standard,
and also a high sensitivity and specificity of the diagno-
sis of DM. The information obtained from the CCR pro-
vides a good estimation of the true prevalence of the
illness, overall and in each category of sex and age
groups.
For HTN, there was also a good overall agreement of
the diagnosis in the CCR with the gold standard, high
Sp and Sn, but lower than for diabetes. In patients with
DM subgroup, the agreement was strikingly lower espe-
cially at the expense of Sn, because the under-diagnosis
of HTN is much higher and the NPV, very influenced
by the prevalence, is ostensibly lower. Similar results, of
less magnitude, are found in the subgroup of patients
aged 70 or over.
In our study the DM diagnosis was confirmed in
99.53% of the cases and HTN in 98.11%.
The systematic review of GPRD validation studies by
Herrett and cols [6] shows that the different diagnoses
studied were confirmed in 89% of the cases, although
DM and HTN were not validated. Only a small propor-
tion of the studies provided quantitative estimates of
validity such as sensitivity and specificity.
We have not found published studies that used similar
methodology to ours for the validation of HTN and DM
diagnoses. For this reason, our results can only be com-
pared with most similar validation studies, which used
self-reported diagnosis by patients compared to bio-
metric measures as reference standards.
The Sn obtained in our study for the diagnosis of DM
(99.53%) is much higher than 69.7% they found in the
DINO study [24], which validates the self-reported diag-
nosis of diabetes, HTN and hyperlipidemia of a popula-
tion of 20 years and older in southern Spain. Published
studies in other countries, also performed with self-
reported diagnosis, present great heterogeneity, with Sn
of DM between 58.9% in a Dutch study [25] and 85.2%
in Taiwan [26].
Regarding the diagnosis of HTN, our Sn was a little
bit lower (85.22%). In Spain, the DINO study estimated
the Sn in 49.4% [24], in a subsample of the SUN study
the Sn was 90.3% [27], and the EPIC Murcia cohort
study obtained a sensitivity of 63.5% [28], taking medical
records as the reference standard. In other countries, we
found values that oscillate between 34.5% in the Dutch
study aforementioned [25], and 82% found in a North-
American study [29].
The high specificity obtained for the diagnosis of DM
(99.49%) is consistent with the findings of other pub-
lished studies, where the Sp is situated between 95.2%
[30] and 99.6% [24]. The Sp obtained for the HTN
(96.95%) is slightly above what was found by other
authors, which oscillated between 80% [31] up to 96.8%
[24].
The agreement found between the diagnosis of DM
registered in the CCR and the fulfillment of the diagno-
s i sc r i t e r i aw e r ev e r yg o o d( k=0 . 9 9 0 ) ,a b o v et h eo n e
obtained in the DINO study (K = 0.78) [24].
For HTN, the agreement (k = 0.778) was lower than
for diabetes, but higher than those found in the DINO
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Page 6 of 11Table 4 Sensivity, specificity and agreement for diabetes mellitus and hypertension.
TN FN FP TP Inter-observers agreement
kappa (CI 95%)
Sensitivity %
(CI 95%)
c
2
p-value
Specificity %
(CI 95%)
c
2
p-value
Diagnostic agreement
kappa (CI 95%)
Diabetes 390 2 2 421 0.988 (0.977 - 0.998) 99.53 (98.29 - 99.87) 99.49 (98.16 - 99.86) 0.990 (0.981 - 1)
- Male 188 1 1 207 0.985 (0.968 - 1) 99.52 (97.33 - 99.92) 1* 99.52 (97.34 - 99.92) 1* 0.990 (0.976 - 1)
- Female 202 1 1 214 0.990 (0.977 - 1) 99.54 (97.41 - 99.92) 99.53 (97.40 - 99.92) 0.990 (0.977 - 1)
- Age < 70 198 1 1 207 0.980 (0.961 - 1) 99.52 (97.33 - 99.92) 1* 99.50 (97.21 - 99.91) 1* 0.990 (0.977 - 1)
- Age ≥ 70 192 1 1 214 0.995 (0.985 - 1) 99.54 (97.41 - 99.92) 99.48 (97.12 - 99.91) 0.990 (0.977 - 1)
Hypertension 254 72 8 415 0.941 (0.916 - 0.967) 85.22 (81.79 - 88.09) 96.95 (94.09 - 98.45) 0.778 (0.732 - 0.823)
- Male 32 32 3 172 0.937 (0.897 - 0.978) 96.95 (94.09 - 98.45) 0.634 97.30 (92.35 - 99.08) 1* 0.770 (0.700 - 0.841)
- Female 40 40 5 243 0.944 (0.911 - 0.977) 85.87 (81.33 - 89.45) 96.69 (92.48 - 98.58) 0.783 (0.724 - 0.842)
- Age < 70 119 18 5 173 0.96 (0.928 - 0.992) 90.58 (85.6 - 93.96) 0.007 95.97 (90.91 - 98.27) 0.482* 0.850 (0.791 - 0.909)
- Age ≥ 70 135 54 3 242 0.926 (0.888 - 0.964) 81.76 (76.96 - 85.74) 97.83 (93.80 - 99.26) 0.724 (0.660 - 0.789)
- Without DM 232 46 7 312 0.947 (0.921 - 0.974) 87.15 (83.29 - 90.23) 0.045 97.07 (94.08 - 98.57) 0.526* 0.947 (0.921 - 0.974)
- With DM 22 26 1 103 0.882 (0.781 - 0.983) 79.85 (72.11 - 85.86) 95.65 (79.01 - 99.23) 0.522 (0.376 - 0.668)
* Fisher’s exact bilateral test; TP: true positive; FP: false positive; TN: true negative; FN: false negative; CI 95%: confidence interval at 95%; DM: diabetes mellitus.
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1Table 5 Apparent prevalence (diagnosis in the CCR), true prevalence (fulfillment of the diagnosis criteria) and
predictive values of diabetes and hypertension.
Apparent prevalence *
(CI 95%)
True prevalence **
(CI 95%)
PPV (CI 95%) NPV (CI 95%)
Diabetes 5.02 (4.96 - 5.07) 5.06 (5.01 - 5.12) 91.23 (72.30 - 97.64) 99.98 (99.90 - 99.99)
- Male 5.61 (5.53 - 5.70) 5.67 (5.58 - 5.75) 92.59 (63.89 - 98.88) 99.97 (99.80 - 100)
- Female 4.55 (4.48 - 4.62) 4.59 (4.52 - 4.66) 91.11(59.19 - 98.64) 99.98 (99.84 - 100)
- Age < 70 2.89 (2.84 - 2.93) 2.91 (2.87 - 2.96) 85.58 (45.66 - 97.67) 99.99 (99.90 - 100)
- Age ≥ 70 15.72 (15.50 - 15.94) 15.87 (15.65 - 16.09) 97.32(83.69 - 99.61) 99.91 (99.38 - 99.99)
Hypertension 14.11 (14.03 - 14.20) 17.14 (17.05 - 17.23) 85.24 (74.46 - 91.96) 96.94 (96.24 - 97.52)
- Male 13.31 (13.18 - 13.43) 16.27 (16.13 - 16.41) 85.84 (66.47 - 94.88) 96.96 (95.87 - 97.78)
- Female 14.75 (14.63 - 14.86) 17.82 (17.70 - 17.95) 84.90 (70.34 - 93.02) 96.93 (95.94 - 97.68)
- Age < 70 7.75 (7.68 - 7.82) 8.91 (8.84 - 8.99) 68.72 (48.18 - 83.85) 99.05 (98.53 - 99.39)
- Age ≥ 70 46.07 (45.77 - 46.36) 57.86 (57.56 - 58.15) 98.10 (94.40 - 99.37) 79.61 (75.40 - 83.27)
- Without DM 11.66 (11.58 - 11.74) 13.81 (13.72 - 13.89) 82.52 (69.44 - 90.74) 97.94 (97.32 - 98.42)
- With DM 60.60 (60.07 - 61.14) 80.22 (79.78 - 80.65) 98.68 (91.62 - 99.80) 53.92 (45.09 - 62.52)
PPV: positive predictive value; NPV: negative predictive value; CI 95%: confidence interval at 95%.
Table 6 Predictive values for hypertension and diabetes for different prevalences (sensitivity analysis).
Prevalence Diabetes Hypertension
PPV (CI 95%) NPV (CI 95%) PPV (CI 95%) NPV (CI 95%)
4% 89.05 (67.11 - 97.01) 99.98 (99.92 - 100) 53.76 (36.99 - 69.72) 99.37 (99.22 - 99.49)
4.5% 90.19 (69.76 - 97.34) 99.98 (99.91 - 99.99) 56.80 (39.91 - 72.26) 99.29 (99.12 - 99.42)
5% 91.13 (72.04 - 97.61) 99.98 (99.90 - 99.99) 59.50 (42.59 - 74.42) 99.20 (99.02 - 99.36)
5.5% 91.91 (74.02 - 97.84) 99.97 (99.89 - 99.99) 61.89 (45.06 - 76.29) 99.12 (98.91 - 99.29)
6% 92.57 (75.76 - 98.02) 99.97 (99.88 - 99.99) 64.05 (47.36 - 77.91) 99.04 (98.81 - 99.22)
6.5% 93.13 (77.29 - 98.18) 99.97 (99.87 - 99.99) 65.99 (49.49 - 79.35) 98.95 (98.70 - 99.15)
7% 93.62 (78.66 - 98.32) 99.96 (99.86 - 99.99) 67.75 (51.47 - 80.62) 98.87 (98.60 - 99.08)
7.5% 94.05 (79.88 - 98.44) 99.96 (99.85 - 99.99) 69.35 (53.33 - 81.76) 98.78 (98.49 - 99.01)
8% 94.43 (80.98 - 98.54) 99.96 (99.84 - 99.99) 70.82 (55.07 - 82.78) 98.69 (98.38 - 98.94)
8.5% 94.77 (81.98 - 98.63) 99.96 (99.82 - 99.99) 72.17 (56.69 - 83.70) 98.60 (98.28 - 98.87)
9% 95.07 (82.88 - 98.72) 99.95 (99.81 - 99.99) 73.41 (58.22 - 84.54) 98.51 (98.17 - 98.80)
9.5% 95.34 (83.71 - 98.79) 99.95 (99.80 - 99.99) 74.55 (59.67 - 85.30) 98.42 (98.06 - 98.72)
10% 95.59 (84.47 - 98.86) 99.95 (99.79 - 99.99) 75.62 (61.03 - 86.00) 98.33 (97.94 - 98.65)
11% 96.02 (85.82 - 98.97) 99.94 (99.77 - 99.99) 77.53 (63.53 - 87.23) 98.15 (97.72 - 98.50)
12% 96.38 (86.97 - 99.07) 99.94 (99.74 - 99.98) 79.19 (65.77 - 88.29) 97.96 (97.49 - 98.35)
13% 96.68 (87.98 - 99.15) 99.93 (99.72 - 99.98) 80.66 (67.80 - 89.20) 97.77 (97.25 - 98.19)
14% 96.95 (88.85 - 99.22) 99.92 (99.69 - 99.98) 81.96 (69.64 - 90.00) 97.58 (97.02 - 98.04)
15% 97.18 (89.63 - 99.28) 99.92 (99.67 - 99.98) 83.12 (71.32 - 90.70) 97.38 (96.77 - 97.87)
20% 97.99 (92.45 - 99.49) 99.88 (99.53 - 99.97) 87.46 (77.89 - 93.25) 96.33 (95.49 - 97.02)
25% 98.49 (94.23 - 99.62) 99.84 (99.37 - 99.96) 90.29 (82.45 - 94.85) 95.16 (94.08 - 96.06)
30% 98.82 (95.45 - 99.70) 99.80 (99.20 - 99.95) 92.28 (85.80 - 95.95) 93.87 (92.51 - 94.99)
35% 99.06 (96.35 - 99.76) 99.75 (98.99 - 99.94) 93.76 (88.36 - 96.75) 92.41 (90.77 - 93.78)
40% 99.24 (97.03 - 99.81) 99.68 (98.75 - 99.92) 94.90 (90.38 - 97.36) 90.77 (88.81 - 92.42)
45% 99.38 (97.56 - 99.84) 99.61 (98.47 - 99.90) 95.80 (92.02 - 97.84) 88.91 (86.61 - 90.85)
50% 99.49 (98.00 - 99.87) 99.53 (98.14 - 99.88) 96.54 (93.37 - 98.22) 86.77 (84.11 - 89.04)
PPV: positive predictive value; NPV: negative predictive value; CI 95%: confidence interval at 95%.
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in the SUN (k = 0.66) [27].
The validation indexes obtained in our study are
higher than those found by other authors, possibly
because we have checked the diagnosis done by physi-
cians and not those self-reported by patients.
Our study confirms the hypothesis found in other
publications in which DM diagnosis has higher validity
than HTN diagnosis [25,30,32]. This could be related to
the perceived higher seriousness of physicians for DM
than for HTN, and due to the DM diagnostic criteria
that were changed less frequently and more uniform
than those for HTN. In general, the parameters of valid-
ity found enable us to realize a precise estimation of the
prevalence of diabetes [33] but a sub-estimation of the
prevalence of HTN.
The under-diagnosis of HTN is a well-known phe-
nomenon whose magnitude varies greatly in published
studies. In a systematic review of 44 studies from differ-
ent countries published in 2009 [34], the proportion of
undiagnosed HTN on a worldwide level was estimated
to be 46.2% for men and 58.5% for women. Different
Spanish studies offer results from 14.9% in Navarra [27],
to 49.4% in Galicia [35] and 31.74% obtained in the
PREDIMERC study in Madrid [36]. In our study, we
found 21.45% in global and 32.36% in the subgroup of
patients with diabetes.
Very little is known about the prevalence of undiag-
nosed HTN in diabetic patients. In Spain, the DIAPA
study found that 56.8% of patients with type 2 DM had
BP > 130/85 mmHg, even though they were not pre-
viously diagnosed with HTN [37]. The lack of HTN
diagnosis in patients with DM could be related to the
cutoff values of diagnosis, which are lower for these
patients (BP ≥ 130/80 mmHg) [10], and it is possible
that some GPs had been using the diagnostic criteria of
the general population (BP ≥ 140/90 mmHg).
When stratifying by sex and age groups, there were
significant differences in the Sn of HTN with worse
results in patients with DM and in those over 69 years,
despite the fact that these patients are subject to a large
number of revisions and so there were more chances to
detect HTN. These results are different than other stu-
dies [24,25,27,28,30,32], where better results were
obtained in older and diabetic patients. One possible
explanation could be that other studies were done
through questionnaires with volunteer participants. The
methods used may have resulted in a selection bias,
since the patients who are more worried about their
health and those who have worse perception of their
health may be more predisposed to participate.
T h et r u ep r e v a l e n c eo fD Mi no u rs t u d yw a s5 . 0 6 % ,
which is very similar to the obtained with the BIFAP
database (5.8%) [8] and in the Spanish National Health
Survey (4.79%) [38] but lower than 8.1% in the PREDI-
MERC study in Madrid [36].
The true prevalence of HTN in our study (17.14%) is
similar to those obtained with the BIFAP database
(16.1%) [8] and in the Spanish National Health Survey
(18.89%) [38] but also lower than the findings in other
studies in Spain. These studies found about 35% in the
adult population [39] and 29.3% in the PREDIMERC
study [36].
This differences observed in the magnitude of the pre-
valences could be due to the age of the patients
included in PREDIMERC [36]. The patient range age
was between 30 and 74 whereas our study includes all
those aged 18 and over. If we had selected people aged
30 or over in our database, the true prevalence would
have been 6.87% for DM and 23.72% for HTN.
Moreover, PREDIMERC was undertaken with volun-
teers, with an overall response rate of 56.4%, which may
have produced a selection bias as was mentioned before.
Furthermore, we cannot assure that false positives were
due to misdiagnosis, simply that the verification of diag-
nostic criteria could not be met. This may have led to
an underestimation of the prevalence in our study.
The prevalence of HTN in diabetic patients obtained
in our study (80.22%) is close to the highest found in
the studies published, which oscillate between 50% and
84% [37,40].
The study presents some limitations. These are that
the information included may not have been completely
exhaustive. Because of this a potential selection bias
m a ye x i s t .T h i si sp a r t i c u l a r l yt r u ei nv i e wo ft h ep r o -
portion of adults in nursing homes, chronic disease hos-
pitals, or those treated in private practice. In addition,
as the health area 4 in Madrid covers only urban popu-
lation, patients living in rural areas were not represented
in this study.
Alternatively, more than 95% of citizens have public
health coverage with the Spanish National Health Sys-
tem [41], so we suppose that the proportion of assigned
persons in the health area 4 who are not included in
our study is low.
The high proportion of patients without available
information to perform the validation (7.3% had not at
least one plasma glucose level and 22.9% had not two or
more BP measurements) could be due to the fact that
these patients do not usually go to health centers. At
least one or two years of active data are basically
required in order to include clinical patient records in a
study.
In both the GPRD and the BIFAP, GPs who volunta-
rily participate in the projects are the ones that refer the
information, possibly introducing a selection bias (e.g.
the pattern of patients care can differ among volunteer
physicians and those who are not volunteers).
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tionnaires can be low, as occurred in BIFAP with the
validation of Upper Gastrointestinal Bleeding with a rate
of the 58.4% [8]. Our database is exhaustive, containing
information from the entire population attended in the
health area, and registered by all the professionals,
avoiding the possibility of the mentioned biases.
Published studies related to validation are aimed to
show whether cases with diagnostic codes indeed have
that condition. The use of the PPV as the only measure-
ment presents the inconvenience that it depends on the
prevalence of the disease, as shown in Table 6. Another
weakness of these validation studies is that, with a few
exceptions, they do not address the question of false
negatives, which are cases of the disease who have not
received a diagnostic code. There were missed cases in
which the GPs did not make the diagnosis or when
made diagnosis but encoded it wrong [42]. We argue
t h a ti na n yv a l i d a t i o ns t u d y ,P P V ,N P V ,S n ,a n dS p
should be identified, as far as possible.
The validation of the diagnosis of CCR of PHC has
facilitated the detection of areas of improvement in the
clinical practice, such as under-diagnosis of HTN with
differential classification bias for patients who also suf-
fers diabetes.
These findings can be used to alert clinicians of sub-
groups for which the interventions could be more
beneficial.
The use of secondary sources of information stored in
computerized databases enables access data from large
populations. This can facilitate the rapid identification
of patients for observational studies or inclusion in
interventions and may reduce the time and resources
needed to obtain results. This greater efficiency consti-
tutes one of the main advantages for using the databases
as epidemiological research tools.
Conclusions
The results obtained in this validation enable the usage
of both DM and HTN diagnoses codes of the computer-
ized clinical records of PHC as a valid tool, which can
be used with confidence to perform epidemiological
studies.
However, the HTN diagnosis in the CCR has lower
sensitivity than DM diagnosis, especially in diabetic
patients. Therefore, in this group of patients, the code
of HTN diagnosis in the CCR is not enough in order to
detect people without HTN since there would be
selected a high amount of false negative results.
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